Tenax Therapeutics, Inc.

Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol